Nautilus Biotechnology, Inc.

Thank you for standing by and welcome to the Nautilus 3rd Quarter 2023 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during the session, you'll need to press star 1-1 on your telephone. To remove yourself from the queue, simply press star 1-1 again. As a reminder, today's program is being recorded. And now I'd like to introduce your host for today's program, Carrie Mandeville at Vesta Relations. Please go ahead.

Thank you. Earlier today, Nautilus released financial results for the quarter ended September 30th, 2023. If you haven't received this news release, or if you'd like to be added to this company's distribution list, please send an email to investorrelations at nautilus.bio. Joining me today from Nautilus are Sujit Patel, co-founder and CEO, Parag Malik, co-founder and chief scientist, and Anna Mowry, chief financial officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled Forward-Looking Statements in the Press Release Nautilus Issue today. Except as required by law, Nautilus disclaims any intention or obligation to update or revise any financial or product pipeline projections or other forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast October 31, 2023. With that, I'll turn the call over to Sujal.

Thanks, Keri. Good morning, and thank you for joining us today. On this call, we'll share our financial results for the third quarter and provide a brief update on recent activities. I'm excited by the progress we made in Q3 against our scientific and development goals and in the ways we're preparing the various elements of our platform for commercial launch. That continued progress is the direct result of the great work being done by Nautilites across all parts of the business, especially, but not limited to, our R&D organizations. I'm pleased to report that as of mid-September, our 100-plus person R&D organization now reports entirely into Subra Sankar, our SVP of product development, who's been with us for almost three years. Though it's only been a little over a month since we've made the change, we've already begun to see the productivity and efficiency gains we'd envisioned. Subra has held many senior roles over the last two decades, notably at Celexa and Illumina, where he led instrumented consumable development efforts for next-generation sequencers and related products. Based on his extensive and successful product development experience, it has been our plan from the beginning to unite these efforts under Subra. With our product development efforts reaching the integration, verification, and scale-up stage, our needs match Subra's experience, making now the right time to effect the change. Unifying R&D under SUBRA has the additional benefit of enabling Parag to significantly expand his outward-facing activities with the scientific and customer communities, while also maintaining deep involvement in both broad strategic issues and day-to-day scientific activities. Joining SUBRA's team just yesterday, we're excited to welcome Dr. Martin Huber as our VP of Biochemistry and Flow Cell Development. For the past 13 years, Martin was a co-founder, CTO, and ultimately CEO of Quantipore, a company devoted to pioneering massively parallel, direct, single-molecule DNA and protein analytical tools. Prior to that, he held senior scientist positions at IonTorrent and Nanosphere. His deep expertise in chemistry and nanoengineering will not only broaden our team's skill set, but also increase the depth of our R&D leadership bench. With an increasing focus on proteomics by the scientific community, moves by major life sciences companies to expand their proteomics-related offerings, and massive international investments in the study of proteins, it's clear to me that the foundation has been laid for the proteomics era of biology and medicine to take root and flourish. While the near-term opportunities that will emerge are exciting areas of focus for us, we believe that easy-to-use high-throughput discovery platforms that match the scale of the proteome, like Nautilus, hold the opportunity to revolutionize more than just proteomics. We believe that the potential exists to fundamentally improve the way all biological research is conducted, improvements that could manifest significant advances to human health for millions across the world. In advance of making our platform available next year, we continue to broadly share, through white papers, scientific posters and presentations, one-on-one briefings, webinars, and a range of other methods, insight into how our platform works and its potential benefits. This type of transparency continues to build meaningful trust and early credibility with our potential buying audiences and underscores our philosophy of being a committed and contributing member of the broader proteomics community. One recent event, the HUPO World Congress in mid-September in Busan, South Korea, provided a great opportunity to continue to educate KOLs and others about our platform and the ways in which we believe it will change what is possible in proteomics research. For more on that and an update on our R&D progress, I'll now turn the call over to Parag.